EGFR and non-small cell lung carcinoma: Osimertinib is SOC in advanced-stage EGFR-mutant NSCLC in the first- or second-line setting (in second-line, the occurrence of an EGFR T790M mutation of resistance to first- or second-generation EGFR TKIs is required) [6,7,35].